Shikonin Derivatives from
Animals
Antineoplastic Agents, Phytogenic
/ chemistry
Apoptosis
Boraginaceae
/ chemistry
Cell Line
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Inhibitory Concentration 50
Leukemia
/ metabolism
Male
Membrane Proteins
Mice
Mice, Inbred BALB C
Naphthoquinones
/ chemistry
Phosphoproteins
STAT3 Transcription Factor
/ genetics
BCL1
JVM-13
Onosma visianii
STAT3
isobutyrylshikonin
α-methylbutyrylshikonin
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
31 Mar 2021
31 Mar 2021
Historique:
received:
28
02
2021
revised:
21
03
2021
accepted:
24
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Antitumor effects of shikonins on chronic lymphocytic leukemia (CLL) and B-cell prolymphocytic leukemia (B-PLL) are mostly unexplored. The antitumor activity of shikonins, isolated from
Identifiants
pubmed: 33807148
pii: nu13041147
doi: 10.3390/nu13041147
pmc: PMC8065735
pii:
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Membrane Proteins
0
Naphthoquinones
0
Phosphoproteins
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
Stat3 protein, mouse
0
p112 protein, rat
0
shikonin
3IK6592UBW
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
N Engl J Med. 2016 Jan 28;374(4):311-22
pubmed: 26639348
Blood. 2012 Jul 19;120(3):538-51
pubmed: 22649104
Anat Cell Biol. 2014 Mar;47(1):1-11
pubmed: 24693477
Cancers (Basel). 2019 Dec 04;11(12):
pubmed: 31817171
Mol Interv. 2011 Feb;11(1):18-26
pubmed: 21441118
Int J Cancer. 2017 Nov 15;141(10):2076-2081
pubmed: 28722170
Cancer Res. 1999 Jul 1;59(13):3077-83
pubmed: 10397248
Mol Med Rep. 2017 Sep;16(3):3055-3060
pubmed: 28713949
Planta Med. 2013 Dec;79(18):1685-97
pubmed: 24155261
EXCLI J. 2020 Jan 03;19:48-70
pubmed: 32038116
Oxid Med Cell Longev. 2018 Jan 11;2018:3853409
pubmed: 29576846
Cancer Cell Int. 2018 Apr 4;18:53
pubmed: 29636641
EXCLI J. 2017 Feb 16;16:73-88
pubmed: 28435429
Cell Res. 2008 Aug;18(8):879-88
pubmed: 18663379
Int J Oncol. 2018 Jul;53(1):339-348
pubmed: 29750424
Oncol Lett. 2017 Aug;14(2):2131-2136
pubmed: 28781654
Sci Rep. 2015 May 14;5:10194
pubmed: 25973915
Oncogene. 2005 Apr 18;24(17):2909-15
pubmed: 15838524
Genes Dev. 1999 Jun 15;13(12):1501-12
pubmed: 10385618
Pharm Biol. 2019 Dec;57(1):412-423
pubmed: 31230505
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2662-2669
pubmed: 31257936
J Clin Invest. 2005 Mar;115(3):755-64
pubmed: 15711642
J Biol Chem. 1999 May 14;274(20):13961-9
pubmed: 10318807
Immunity. 2006 Jun;24(6):703-16
pubmed: 16782027
Br J Haematol. 1974 May;27(1):7-23
pubmed: 4137136
Nat Prod Res. 2018 Nov;32(22):2712-2716
pubmed: 28882053
Blood. 2010 Apr 8;115(14):2852-63
pubmed: 20154216
Cell Biol Toxicol. 2011 Feb;27(1):13-40
pubmed: 20589437
Blood. 2011 May 12;117(19):5019-32
pubmed: 21300984
J Biomed Sci. 2015 Apr 01;22:26
pubmed: 25879420
Cell Physiol Biochem. 2018;47(3):981-993
pubmed: 29843123
Evid Based Complement Alternat Med. 2013;2013:818709
pubmed: 23861714
Nature. 1993 Dec 16;366(6456):701-4
pubmed: 8259214